[1] |
SABATTINI E, PIZZI M, TABANELLI V, et al. CD30 expression in peripheral T-cell lymphomas[J]. Haematologica, 2013, 98(8): e81-e82.
doi: 10.3324/haematol.2013.084913
|
[2] |
WANG G N, ZHAO W G, LI L, et al. Prognostic significance of CD30 expression in nasal natural killer/T-cell lymphoma[J]. Oncol Lett, 2017, 13(3): 1211-1215.
doi: 10.3892/ol.2017.5592
|
[3] |
HU S M, XU-MONETTE Z Y, BALASUBRAMANYAM A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the international DLBCL rituximab-CHOP consortium program study[J]. Blood, 2013, 121(14): 2715-2724.
doi: 10.1182/blood-2012-10-461848
pmid: 23343832
|
[4] |
FRANCISCO J A, CERVENY C G, MEYER D L, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity[J]. Blood, 2003, 102(4): 1458-1465.
doi: 10.1182/blood-2003-01-0039
pmid: 12714494
|
[5] |
PRO B, ADVANI R, BRICE P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase Ⅱ study[J]. J Clin Oncol, 2012, 30(18): 2190-2196.
doi: 10.1200/JCO.2011.38.0402
|
[6] |
YOUNES A, GOPAL A K, SMITH S E, et al. Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma[J]. J Clin Oncol, 2012, 30(18): 2183-2189.
|
[7] |
NORDI Q C. Control N-IQ. CD30[M]. 2017.
|
[8] |
LI B, ESCHRICH S A, BERGLUND A, et al. Use of the total cancer care system to enrich screening for CD30-positive solid tumors for patient enrollment into a brentuximab vedotin clinical trial: a pilot study to evaluate feasibility[J]. JMIR Res Protoc, 2017, 6(3): e45.
doi: 10.2196/resprot.7289
|
[9] |
HIRSCH F R, VARELLA-GARCIA M, BUNN P A Jr, et al. Epidermal growth factor receptor in non-small cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis[J]. J Clin Oncol, 2003, 21(20): 3798-3807.
doi: 10.1200/JCO.2003.11.069
|
[10] |
KIM H K, MOON S M, MOON J H, et al. Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin[J]. Blood Res, 2015, 50(4): 254-256.
doi: 10.5045/br.2015.50.4.254
pmid: 26770954
|
[11] |
PRINCE H M. CD30 As a target for the treatment of cutaneous T-cell lymphoma[J]. J Clin Oncol, 2015, 33(32): 3691-3696.
doi: 10.1200/JCO.2015.61.9486
pmid: 26392103
|
[12] |
XU M L, GABALI A, HSI E D, et al. Practical approaches on CD30 detection and reporting in lymphoma diagnosis[J]. Am J Surg Pathol, 2020, 44(2): e1-e14.
doi: 10.1097/PAS.0000000000001368
|
[13] |
《淋巴瘤病理诊断规范》项目组. 淋巴组织肿瘤病理诊断规范[J]. 中华病理学杂志, 2019, 48(5): 346-349.
|
|
The Project Team of Standardization for Diagnosis Tumor Pathology of Lymphomas. Standardization for diagnosis tumor pathology of lymphomas[J]. Chin J Pathol, 2019, 48(5): 346-349.
|
[14] |
李小秋, CD30阳性淋巴瘤病理专家组. CD30在淋巴瘤中的表达及检测:现状与挑战[J]. 中国癌症杂志, 2022, 32(6): 512-518.
doi: 10.19401/j.cnki.1007-3639.2022.06.005
|
|
LI X Q. CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges[J]. China Oncol, 2022, 32(6): 512-518.
|